We had the great pleasure to meet with Jessica Ailani (MedStar Georgetown Headache Center, Georgetown, WA, USA) to discuss the Phase 3 ADVANCE study (NCT03777059) results investigating atogepant for the treatment of migraine.
The abstract entitled: ‘Atogepant Significantly Reduces Mean Monthly Migraine Days in the Phase 3 Trial (ADVANCE) for the Preventive Treatment of Migraine‘ was presented at the American Academy of Neurology Virtual Annual Meeting 2021.
Questions:
- What were the aims and design of the ADVANCE study? (0:18)
- What did the ADVANCE study findings show in terms of reductions in mean monthly migraine days? (1:14)
- How did these reductions in migraine days compare with those seen with antibody-based CGRP antagonists? (1:44)
Disclosures: Jessica Ailani has been an independent consulting (received honoraria) for Amgen, Abbvie, Biohaven, Eli Lilly and Company, GlaxoSmithKline, Lundbeck, Teva, Impel, Satsuma, Axsome, Vorso, Aeon, Theranica, Medscape; and has ownership of Stocks in CtrM; and is on part of the Speakers Bureau, and received honoraria for promotional speaking from Allergan/Abbvie, Amgen, Biohaven, Eli Lilly and Company, Lundbeck, Teva; and has provided editorial services (Honoraria) to Current Pain and Headache Reports, Section editor, Unusual Headache Syndromes, NeurologyLive, Infomedica (AHS Virtual Highlights 2020), SELF (medical reviewer). Jessica Ailani has also received Clinical Trial grants from (Fees to Institution) American Migraine Foundation, Allergan/Abbvie, Biohaven, Eli Lilly and Company, Satsuma and Zosano.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Katey Gabrysch.
Filmed as a highlight of AAN Annual Virtual Meeting 2021.
